158 related articles for article (PubMed ID: 38547427)
1. Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides.
Dungan L; Dunne J; Savio M; Kalaszi M; McElheron M; Lynagh Y; O'Driscoll K; Roche C; Qureshi A; Crowley B; Conlon N; Kearney H
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200217. PubMed ID: 38547427
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
[TBL] [Abstract][Full Text] [Related]
3. Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis.
Thomas OG; Haigh TA; Croom-Carter D; Leese A; Van Wijck Y; Douglas MR; Rickinson A; Brooks JM; Taylor GS
PLoS Pathog; 2024 Jun; 20(6):e1012177. PubMed ID: 38843296
[TBL] [Abstract][Full Text] [Related]
4. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.
Jilek S; Schluep M; Meylan P; Vingerhoets F; Guignard L; Monney A; Kleeberg J; Le Goff G; Pantaleo G; Du Pasquier RA
Brain; 2008 Jul; 131(Pt 7):1712-21. PubMed ID: 18550621
[TBL] [Abstract][Full Text] [Related]
5. Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy.
Rød BE; Wergeland S; Bjørnevik K; Holmøy T; Ulvestad E; Njølstad G; Myhr KM; Torkildsen Ø
Mult Scler Relat Disord; 2023 Nov; 79():105037. PubMed ID: 37804765
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.
Ascherio A; Munger KL; Lennette ET; Spiegelman D; Hernán MA; Olek MJ; Hankinson SE; Hunter DJ
JAMA; 2001 Dec; 286(24):3083-8. PubMed ID: 11754673
[TBL] [Abstract][Full Text] [Related]
7. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.
Lünemann JD; Jelcić I; Roberts S; Lutterotti A; Tackenberg B; Martin R; Münz C
J Exp Med; 2008 Aug; 205(8):1763-73. PubMed ID: 18663124
[TBL] [Abstract][Full Text] [Related]
8. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus and disease activity in multiple sclerosis.
Buljevac D; van Doornum GJ; Flach HZ; Groen J; Osterhaus AD; Hop W; van Doorn PA; van der Meché FG; Hintzen RQ
J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1377-81. PubMed ID: 16170080
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis and Epstein-Barr virus.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2003 Mar; 289(12):1533-6. PubMed ID: 12672770
[TBL] [Abstract][Full Text] [Related]
11. A different response to cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection in UK people with multiple sclerosis (PwMS) compared to controls.
Maple PAC; Tanasescu R; Gran B; Constantinescu CS
J Infect; 2020 Mar; 80(3):320-325. PubMed ID: 31678173
[TBL] [Abstract][Full Text] [Related]
12. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
Nystad TW; Myrmel H
J Clin Virol; 2007 Apr; 38(4):292-7. PubMed ID: 17336144
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
Castellazzi M; Delbue S; Elia F; Gastaldi M; Franciotta D; Rizzo R; Bellini T; Bergamaschi R; Granieri E; Fainardi E
Dis Markers; 2015; 2015():901312. PubMed ID: 26101453
[TBL] [Abstract][Full Text] [Related]
15. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
16. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M
Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504
[TBL] [Abstract][Full Text] [Related]
17. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.
Sundström P; Juto P; Wadell G; Hallmans G; Svenningsson A; Nyström L; Dillner J; Forsgren L
Neurology; 2004 Jun; 62(12):2277-82. PubMed ID: 15210894
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.
Kvistad S; Myhr KM; Holmøy T; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Løken-Amsrud KI; Lilleås F; Midgard R; Njølstad G; Pedersen T; Benth JŠ; Wergeland S; Torkildsen O
Mult Scler; 2014 Dec; 20(14):1833-40. PubMed ID: 24842958
[TBL] [Abstract][Full Text] [Related]
19. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis.
Jafari N; van Nierop GP; Verjans GM; Osterhaus AD; Middeldorp JM; Hintzen RQ
J Clin Virol; 2010 Sep; 49(1):26-31. PubMed ID: 20638898
[TBL] [Abstract][Full Text] [Related]
20. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis.
Cortese M; Leng Y; Bjornevik K; Mitchell M; Healy BC; Mina MJ; Mancuso JD; Niebuhr DW; Munger KL; Elledge SJ; Ascherio A
JAMA Neurol; 2024 May; 81(5):515-524. PubMed ID: 38497939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
